CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Chiusa

SettoreTop Industriali

210.17 0.15

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

209.19

Massimo

210.4

Metriche Chiave

By Trading Economics

Entrata

2B

Vendite

-5.7B

2.5B

P/E

Media del settore

21.941

38.367

EPS

2.04

Rendimento da dividendi

1.39

Margine di Profitto

24.437

Dipendenti

29,904

EBITDA

-2.4B

858M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.44% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.39%

2.26%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-24B

100B

Apertura precedente

210.02

Chiusura precedente

210.17

Notizie sul Sentiment di mercato

By Acuity

38%

62%

142 / 459 Classifica in Industrials

CSL Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 ago 2025, 03:32 UTC

I principali Market Mover

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 ago 2025, 23:46 UTC

Utili

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 ago 2025, 22:15 UTC

Utili

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 apr 2025, 09:39 UTC

I principali Market Mover

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 feb 2025, 21:55 UTC

Utili

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Utili

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18 ago 2025, 23:46 UTC

Discorsi di Mercato
Utili

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 ago 2025, 21:52 UTC

Utili

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 ago 2025, 21:51 UTC

Utili

CSL to Cut Up to 15% of Staff>CSL.AU

18 ago 2025, 21:49 UTC

Utili

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 ago 2025, 21:49 UTC

Utili

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 ago 2025, 21:48 UTC

Utili

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 ago 2025, 21:47 UTC

Utili

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 ago 2025, 21:46 UTC

Utili

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 ago 2025, 21:45 UTC

Utili

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 ago 2025, 21:45 UTC

Utili

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 ago 2025, 21:44 UTC

Utili

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 ago 2025, 21:43 UTC

Utili

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 ago 2025, 21:43 UTC

Utili

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 ago 2025, 21:42 UTC

Utili

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 ago 2025, 21:42 UTC

Utili

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 giu 2025, 02:15 UTC

Discorsi di Mercato

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 apr 2025, 07:01 UTC

Discorsi di Mercato

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mar 2025, 02:03 UTC

Discorsi di Mercato

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Discorsi di Mercato

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Utili

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Utili

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Utili

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Utili

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Utili

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Confronto tra pari

Modifica del prezzo

CSL Ltd Previsione

Obiettivo di Prezzo

By TipRanks

35.44% in crescita

Previsioni per 12 mesi

Media 283.415 AUD  35.44%

Alto 330 AUD

Basso 227.5 AUD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CSL Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Sentiment

By Acuity

142 / 459 Classifica in Top Industriali

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat